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Pediatric cranial radiotherapy (CrRT) markedly increases risk of meningiomas. We studied 
meningioma risk factors with emphasis on independent and joint effects of CrRT dose, exposed 
cranial volume, exposure age, and chemotherapy.  
Methods 
The DCOG-LATER cohort includes five-year childhood cancer survivors (CCSs) diagnosed 1963-2001. 
Histologically confirmed benign meningiomas were identified from the population-based Dutch 
Pathology Registry (PALGA; 1990-2015). We calculated cumulative meningioma incidence and used 
multivariable Cox regression and linear excess relative risk (ERR) modelling. 
Results 
Among 5,843 CCSs (median follow-up: 23.3 years, range: 5.0-52.2 years), 97 developed a benign 
meningioma, including 80 after full- and 14 after partial-volume CrRT. Compared to CrRT doses of 1-
19 Gy, no CrRT was associated with a low meningioma risk (HR=0.04,95%CI:0.01-0.15), while 
increased risks were observed for CrRT doses 20-39 Gy (HR=1.66,95%CI:0.83-3.33) and 40+ Gy 
(HR=2.81,95%CI: 1.30-6.08). CCSs diagnosed before age 5 vs 10-17 years showed significantly 
increased risks (HR=2.38,95% CI:1.39-4.07). In this dose-adjusted model, volume was not significantly 
associated with increased risk (HR full vs. partial=1.66,95%CI:0.86-3.22). Overall, the ERR/Gy was 0.30 
(95%CI:0.03-unknown). Dose effects did not vary significantly according to exposure age nor CrRT 
volume. Cumulative incidence after any CrRT was 12.4% (95%CI:9.8%-15.2%) 40 years after primary 
cancer diagnosis. Among chemotherapy agents (including methotrexate and cisplatin), only 
carboplatin (HR=3.55,95%CI:1.62-7.78) appeared associated with meningioma risk. However, we saw 
no carboplatin dose-response and all nine exposed cases had high-dose CrRT. 
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After cranial radiotherapy one in eight survivors developed late meningioma by age 40 years, 
associated with radiation dose- and exposure age, relevant for future treatment protocols and 
awareness among survivors and physicians. 
Keywords 




1 in 8 childhood cancer survivors treated with cranial radiotherapy develops a late meningioma 
 
Meningioma risk is dose dependent with no modification of the dose-response by age or exposed 
volume 
 
Our study contributes new evidence that can be useful for meningioma surveillance 
recommendations 
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Importance of the study 
There is considerable debate on the justification for or against active screening for meningioma 
among asymptomatic childhood cancer survivors. Cranial radiotherapy markedly increases the risk of 
meningioma, however, the roles of exposed cranial volume and age at radiotherapy are unclear. We 
studied a large, well-characterized cohort of childhood cancer survivors with near-complete and 
unbiased assessment of late meningioma via national pathology registration. We found that one in 
eight survivors developed a late meningioma by age 40 years after cranial radiotherapy.  We showed 
evidence for increased risk by radiation dose and among patients treated at the youngest ages, 
however, no significant modification of the radiation dose-response by age nor by radiation-exposed 
cranial volume. Our study contributes new evidence to the key element of adequate risk 
stratification for surveillance recommendations by evaluating the modifying effects of exposed 
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Among childhood cancer survivors (CCSs) who had cranial radiotherapy (CrRT), a markedly elevated 
incidence of subsequent central nervous system (CNS) neoplasms has been established.1 
Meningiomas represent the most common type and, although mostly benign, meningiomas can 
cause serious neurologic morbidity.2 Meningiomas typically occur beyond 10 years after treatment; 
median/mean interval from primary cancer diagnosis to meningioma diagnosis of more than 20 years 
have been reported in large cohort studies among CCSs.2,3 Furthermore, the excess risk does not 
seem to plateau over time.2,4 Meningioma risk appears to increase with increasing radiation dose,2-5 
while the role of exposed cranial volume has not been studied. Some studies reported that a lower 
age at childhood cancer diagnosis was associated with an increased risk of meningioma4,6,7 which 
may reflect a higher sensitivity to radiation, as observed for other tissues (e.g. the thyroid gland).8 
However, studies that evaluated this hypothesis directly, by evaluating meningioma risk among 
CCSs3,5 and among children treated for tinea capitis,9 found no clear variation in the strength of the 
radiation dose-response by exposure age. 
Of all chemotherapy drugs evaluated in two large cohorts of CCSs, platinum agents and intrathecal 
methotrexate were the only ones for which some evidence of excess meningioma risk was 
reported.3,6,7 However, these initial findings have not been replicated. 
Finding the right balance between benefits and drawbacks of active surveillance for CNS tumors, in 
particular meningioma, among asymptomatic individuals who had CrRT, is challenging.2,10 Adequate 
risk stratification is one of several key elements to enable balanced decision making on surveillance 
recommendations, as currently ongoing by the International Guideline Harmonization Group 
(IGHG).11 
We examined the independent and joint effects of CrRT dose, exposed cranial volume, and age at 
childhood cancer treatment to determine excess risk of meningiomas in the Dutch Cancer Oncology 
Group – Long-Term Effects after Childhood Cancer (DCOG-LATER) cohort of five-year CCSs. 
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The full DCOG-LATER cohort includes 6,165 individuals who were treated for childhood cancer 
between 1/1/1963 and 12/31/2001 in one of the seven Dutch pediatric oncology and stem cell 
transplant centers before age 18 years and who survived at least five years after diagnosis. The study 
protocol was exempted from review by institutional review boards of all participating centers. More 
details were reported elsewhere.12 
Cancer diagnosis, treatment information 
Information on prior cancer diagnosis, treatments for primary tumor and all recurrences, and cancer 
predisposition syndromes was collected by dedicated data managers.12 The 1440 survivors who 
received radiotherapy directed to the head – including those who received total body irradiation 
(TBI) – were assigned to one of three subgroups: full-cranial volume (full-CrRT; defined as 100% of 
the cranium in field), partial-cranial volume (partial-CrRT; defined as any CrRT with less than 100% of 
the cranium in field), and radiotherapy to the head without cranial involvement (no brain tissue in 
the field; not considered CrRT). For leukemia, CNS tumors, and retinoblastoma survivors (77.4% of 
1440), two experienced radiation technologists (JLK and AvE) reviewed treatment protocols; for 
other childhood cancer types (19.1%) simulation films or anatomical diagrams in radiotherapy charts 
were used when available. When the radiotherapy record was missing or uninformative, volume was 
assigned by childhood cancer type and protocol (3.5%). The total dose for primary tumor and 
recurrences, including boost dose, was determined. We calculated the total maximum prescribed 
CrRT dose (in case of multiple CrRT treatments for primary tumor or recurrences) as follows: Dose 
was summed when the same location was irradiated (maximum dose to smallest CrRT field was 
assessed). In case of two or more non-overlapping CrRT fields, the dose to the field with the highest 
dose was assigned. 
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Histologically confirmed subsequent benign meningiomas diagnosed between 1/1/1990-5/1/2015 
were identified by linkage based on family name, gender, and date of birth with the nationwide 
network and registry of histo- and cytopathology in the Netherlands (PALGA), which reached 
nationwide coverage in 1990.13 All pathology reports are summarized into short digital excerpts 
which contain one or more codes to classify the result of the pathologist review. These were 
manually reviewed by one author (JLK) to identify eligible cases (morphology codes M9530-9539 and 
brain topography codes (Supplementary Table 1)). In case of doubt, excerpts were discussed with 
two experts, including a late effects outpatient clinic doctor (CMR, HvdP). Cohort members were 
traced for vital status and emigration status as reported previously.12 
Sibling comparison group 
Because no reference rates on histologically confirmed benign meningiomas are available in the 
general population for this predominantly young population, we included a sibling comparison group 
to parallel the meningioma incidence in CCSs to the incidence in the general population. CCSs who 
participated in a 2013-2014 questionnaire survey (N=3,172) were asked to invite their siblings. These 
siblings (N=1663) were approached and after consent 883 (53%) siblings were linked with PALGA as 
described above. 
Statistical analyses 
Survivors who declined -usage of health care data (N=152; 2.5%) and those who died, emigrated, or 
were lost-to-follow-up prior to 1990 (N=170; 2.8%) were excluded. Follow-up started five years after 
childhood cancer diagnosis or 1/1/1990, whichever came last, and ended on the date of diagnosis of 
the first histologically confirmed meningioma, death, last known vital status (emigration/lost-to-
follow-up), or end-of-study (5/1/2015), whichever came first.  
Cumulative incidence of benign meningiomas was estimated, considering death as a competing 
risk.14 Multivariable Cox regression models were used to estimate meningioma risks associated with 
Definition and ascertainment of subsequent meningiomas 
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prescribed CrRT dose (no CrRT, 1-19 Gy, 20-39 Gy, 40+ Gy). To construct a multivariable model, we 
first tested binary indicators for hematopoietic cell transplantation (HCT) and single 
chemotherapeutic agents with at least 5 exposed meningioma cases (n=15) in univariable models. 
Those with a univariable P-value <0.1 were separately tested in models with CrRT dose, exposed 
cranial volume, and basic demographic factors. The final model included, in addition to CrRT dose, 
exposed cranial volume, and basic demographic factors, those binary indicators for HCT and single 
chemotherapeutic agents that remained significantly associated with meningioma risk (P<0.05) or 
that considerably changed the effect of the CrRT dose risk estimate if removed. In addition, we 
calculated the overall linear excess relative risk per Gy (ERR/Gy) among exposed individuals 
(Supplementary Methods). Joint effect of CrRT and other characteristics were assessed in two ways. 
First, we estimated the joint effects of CrRT dose (≤25, >25 Gy) with exposed cranial volume (full-
CrRT, partial-CrRT), and with age at childhood cancer diagnosis as surrogate for CrRT age (<5, ≥5 
years). Since the prescribed CrRT doses show scattered peaks at standard-protocol doses (e.g. 18-25 
Gy, 50-54 Gy, etc.) we classified CCSs simultaneously according to CrRT dose (≤25 Gy vs. >25 Gy) and 
age at childhood cancer diagnosis (<5 vs. 5+ yrs), and CrRT dose and exposed cranial volume. Second, 
we evaluated whether the effects of continuous CrRT dose is modified by age at diagnosis, volume, 
and sex by estimating separate ERRs/Gy for strata of the hypothesized effect modifiers; 
heterogeneity of ERRs/Gy was evaluated with likelihood ratio tests. Non-linearity of the dose-
response relationship was evaluated by testing whether a loglinear modification term for linear dose 
was significantly different from zero. We evaluated proportionality of hazards for each variable in the 
multivariable Cox regression model by adding interaction terms with attained age (the time scale) 
and  found no evidence of non-proportionality. P-values < .05 were considered statistically significant 
and all statistical tests were two-sided. STATA (StataCorp. 2013. Stata Statistical Software: Release 
13. College Station, TX: StataCorp LP) and Epicure software (Risk Sciences International, Ottawa) 
were used.  
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This analysis includes 5,843 five-year CCSs contributing 102,937 person-years at risk during 1/1/1990-
5/1/2015. Median time since childhood cancer diagnosis was 23.3 years (range: 5.0-52.2 years) and 
median attained age at end of follow-up was 30.6 years (range: 5.8-67.5 years). Nearly half of the 
cohort was treated for either leukemia (33.2%) or CNS tumors (13.0%) (Table 1). In total, 1277 
survivors received CrRT, including 956 full-CrRT and 321 partial-CrRT, and another 163 survivors 
received radiotherapy to the head without cranial involvement (Supplementary Figures 1a,1b,1c). 
The proportion of cohort members treated with CrRT strongly decreased over time, i.e. 36.2%, 
18.7%, and 12.5% for those diagnosed in 1963-1984, 1985-1994, and 1995-2001, respectively, largely 
attributed to a strong decline in proportion of patients, mainly leukemia survivors, treated with 20-
39 Gy CrRT; 20.9% in 1963-1984, 2.4% in 1985-1994, 1.2% in 1995-2001 (data not shown). 
Characteristics of survivors with subsequent meningioma 
In total, 97 survivors (1.7%) developed at least one histologically confirmed benign meningioma. 
Among meningioma cases, median time since childhood cancer diagnosis was 24.9 years (range: 8.5-
44.5 years, interquartile range (IQR): 20.6-30.6) and median age at first meningioma diagnosis was 
31.7 years (range: 15.5-49.9 years, IQR: 27.3-36.6). All but three patients with a subsequent benign 
meningioma had a history of CrRT, including 80/94 with full-CrRT for either acute lymphoblastic 
leukemia (ALL; n=48), medulloblastoma (n=19), non-Hodgkin lymphoma (NHL; n=7), acute myeloid 
leukemia (AML; n=3), or a germ cell tumor (n=3) (Table 1). Another 14/94 CrRT patients with 
meningioma had received partial-CrRT for other types of CNS tumors (n=13), or soft tissue sarcoma 
(STS; n=1). Among meningioma patients who received any CrRT, 45.4% received a dose of 40 Gy or 
more compared to 10.6% of CrRT-treated patients in the total cohort. The dose distribution varied 
between the full-CrRT and partial-CrRT group; the majority of partial-CrRT (90.0%) received a dose of 
40 Gy or more, while full-CrRT individuals were more equally distributed over the dose categories 
(Supplementary Figure 2). Two survivors who developed a meningioma after partial-CrRT had a 
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confirmed neurofibromatosis diagnosis: one diagnosed with meningioma 13 years after a nerve 
sheath tumor and one diagnosed 25 years after a glioma. Three patients developed an intervening 
subsequent malignant neoplasm (SMN) before the meningioma was detected; only one received 
CrRT for the SMN and that patient had already received full-CrRT for the childhood cancer. Our 
record linkages with the pathology registry (this paper) and the national cancer registry
12
, revealed five 
malignant meningioma, including four survivors with a preceding benign meningioma and included in 
the analyses presented here. 
Comparison with sibling cohort 
In our sibling cohort (N=883), 1 female developed a meningioma at the age of 45, whereas her sibling 
Hodgkin lymphoma survivor did not. After adjustment for attained age and sex, the incidence of 
meningiomas in the survivor cohort was significantly higher than among siblings (HR=17.79; 95%CI: 
2.48-127.76, P<0.00001). 
Independent effects of demographic and treatment-related risk factors 
In multivariable models, having had any CrRT was a strongly influential factor for meningioma risk. 
Next, of the three related characteristics (dose, volume, age), CrRT dose appeared to be the most 
influential risk factor. Compared to survivors who received 1-19 Gy CrRT dose (10 cases/324 cohort 
members), survivors treated without CrRT had a strongly and significantly lower meningioma risk 
(HR=0.04, 95% CI: 0.01-0.15; 3 cases/4,525 cohort members), while CrRT doses 20-39 Gy (HR=1.66, 
95% CI: 0.83-3.33; 48 cases/445 cohort members) and 40+ Gy (HR=2.81, 95% CI: 1.30-6.08; 35 
cases/493 cohort members) inferred higher risk (Table 2). In other words, the reference group in this 
analysis (1-19 Gy CrRT) had a strongly increased risk compared to the group without CrRT. In the 
same dose-adjusted model , full-CrRT was not significantly associated with increased risk compared 
to partial-CrRT (HR=1.66, 95% CI: 0.86-3.22). In addition to CrRT risk, survivors who had received 
carboplatin (9 cases /409 cohort members) vs. no carboplatin had a statistically significantly 
increased risk (HR=3.55, 95% CI: 1.62-7.78), without evidence for a carboplatin dose-response 
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relationship. Individual chemotherapy agents other than carboplatin (including methotrexate (57 
exposed cases) and cisplatin (2 exposed cases)) were not associated with risk of meningioma. Of 
note, of nine patients with a meningioma after carboplatin-containing regimens, one had a prior 
ependymoma while all eight others received high-dose full-CrRT (primary 30 Gy, boost of >20 Gy to 
the fossa posterior) for medulloblastoma. Median CrRT doses were 55 Gy and 25 Gy for meningeoma 
cases with and without carboplatin, respectively, and this distribution was similar to the difference in 
CrRT dose by carboplatin status in the entire cohort. Without adjustment for CrRT dose, the effect of 
carboplatin was stronger (HR=5.79, 95% CI: 2.80-11.98; data not shown). The demographic factors 
sex (HR=1.36, 95% CI: 0.91-2.04 for females vs. males) and age at childhood cancer diagnosis, (HRs of 
2.38, 95% CI: 1.39-4.07 and 1.09, 95% CI: 0.62-1.91 for ages 0-4 and 5-9 years, respectively, vs. ages 
10-17) were not statistically significantly associated with meningioma risk. Parallel analyses with time 
since rather than age at childhood cancer diagnosis in the model showed HRs of 2.18 (95% CI: 1.13-
4.23) and 3.98 (95% CI: 1.57-10.11) for 20-29 years and >30 years since diagnosis vs. 5-19 years, 
respectively, while risk estimates for other covariates (Table 2, model 1) were not materially altered 
(not shown).  
Combined effects of age/dose and volume/dose categories 
Compared to young patients (<5 year) with a low CrRT dose (≤25 Gy), meningioma risk was 
nonsignificantly increased among young patients with a high CrRT dose (>25 Gy) (HR=1.84, 95%CI: 
0.95-3.56); those treated at older ages (5+ years), regardless of CrRT dose, had significantly lower 
meningioma risk (HR=0.47, 95% CI: 0.27-0.81 for age 5+, ≤25 Gy and HR=0.61, 95%CI: 0.33-1.13 for 
age 5+, >25 Gy) (Table 2, model 2). In contrast, there was no clear effect of exposed cranial volume 
with HRs for survivors treated with full-CrRT at doses ≤25 Gy (HR=1.03, 95% CI: 0.56-1.89) and full 
CrRT at doses >25 Gy (HR =1.45, 95% CI: 0.75-2.83) in comparison with any partial-CrRT (Table 2, 
model 3).  
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When CrRT dose was analyzed as a continuous variable, adjusted for sex, age at diagnosis, and CrRT 
volume (no/partial/full) we observed a statistically significant linear dose-response among CrRT-
exposed individuals (ERR/Gy of 0.30, 95% CI: 0.03-unknown; Table 3, model 1). We found no 
evidence for nonlinearity of the dose-response relationship (p=.62). We did not observe significant 
modifications of the dose-response by age at diagnosis, exposed cranial volume, or sex (Table 3, 
models 2-5).  
Cumulative incidence of subsequent meningioma 
The cumulative incidence of benign meningiomas varied according to CrRT characteristics. For 
survivors treated with CrRT the cumulative incidence was 12.4% (95% CI: 9.8%-15.2%) 40 years after 
diagnosis (Figure 1, panel A) and 7.3% (95% CI: 4.5%-10.8%) by age 45 (Figure 1, Panel B).  For 
survivors without CrRT the cumulative incidence was much lower (0.3%, 95% CI: 0.1%-1.2% 40 years 
after diagnosis (Figure 1, panel A) and 0.3%, 95% CI: 0.1-1.2 by age 45 (Figure 1, panel B)). By CrRT 
doses, the cumulative incidence 40 years after diagnosis were 5.6% (95% CI: 2.3%-11.0%), 13.1%  
(95% CI: 9.6%-17.1%) , and 9.4% (95% CI: 6.3%-13.3%) for 1-19 Gy, 20-39 Gy, and 40+ Gy, respectively 
(Figure 1, panel C). Similar patterns were observed by attained age (Figure 1, panel D). 
When evaluated separately by age at childhood cancer diagnosis, the cumulative incidences of 
meningioma for survivors diagnosed at age 0-4 years, age 5-9 years, and age 10-17 years were 5.2% 
(95% CI: 3.7%-7.1%), 4.3% (95% CI: 2.6%-6.4%), and 3.7% (95% CI: 2.1%-5.9%) 40 years after 
diagnosis (Figure 2, panel A) and 5.3% (95% CI: 3.7%-7.3%), 4.3% (95% CI: 2.6%-6.6%), and 2.4% (95% 
CI: 1.5%-3.5%) by age 45 (Figure 2, panel B), respectively. Fifteen-year cumulative incidences was 
similar across periods of diagnosis (0.2%, 95% CI: 0.1%-0.7% for 1963-1984, 0.1%, 95% CI: 0.0%-0.4% 
for 1985-1994, and 0.1%, 95% CI: 0.0%-0.4% for 1995-2001, Figure 2, panel C). 
Effect modification of continuous CrRT dose with age, volume, and sex 
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Our nationwide study with complete information on histologically confirmed benign meningiomas 
after childhood cancer shows that, after cranial radiotherapy, one in eight survivors developed a late 
meningioma  40 years after primary cancer diagnosis. We found evidence for increased risk by 
radiation dose and among patients treated at the youngest ages, however, no significant 
modification of the radiation dose-response by age nor by radiation-exposed cranial volume. 
CrRT is the most important risk factor for meningioma risk among CCSs; nearly all cases (97%) 
occurred among survivors who were treated with CrRT. Consistent with our findings of a dose-related 
excess risk,  CrRT has frequently been reported to linearly increase risk of meningioma in a dose-
related fashion among young CCSs,3-5 atomic bomb survivors,15 and children treated for tinea capitis,9 
as summarized in Supplementary Table 2. While a main effect of age at childhood cancer diagnosis 
has been reported by others,4,6,7 data are inconsistent as to whether age modifies the radiation dose-
response curve. We hypothesized that younger exposure age, as crude indicator of vulnerability 
during brain development, is related to higher radiation sensitivity, in other words, that the effect of 
radiation dose on meningioma risk varies by age at radiotherapy. Our results did not firmly support 
this hypothesis, consistent with earlier reports by Neglia et al. (66 meningioma cases) and Taylor et 
al. (137 meningioma cases) for the US/Canadian and UK childhood cancer survivor studies.3,5 Our 
analyses are based on prescribed CrRT dose, whereas the latter two studies3,5 used absorbed CrRT 
dose in a case-control setting. Although it can be assumed that the prescribed CrRT dose is almost 
similar to the absorbed dose at the organ at risk, the meninges, for meningioma cases treated with 
full-CrRT (n=80 cases), the prescribed CrRT dose may represent an overestimation of the true 
absorbed dose at the meningioma location for partial-CrRT treated patients (n=14 cases). A new 
aspect of our study is that we analyzed the potential modifying effect of exposed cranial volume on 
the relation between radiation dose and meningioma risk. Our second hypothesis was that a higher 
volume of brain tissue exposed, will increase the radiation dose-related risk of meningioma. We did, 
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however, not find evidence of a stronger dose-response among patients treated with full-CrRT 
compared to those treated with partial-CrRT; there was a suggestive, but nonsignificant main effect 
of full-CrRT (HR=1.66 for full vs partial). Of note, these results need to be interpreted with caution 
owing to a combination of factors: (1) the lack of statistical significance; (2) the probability that CrRT-
volume may be a surrogate of other patient characteristics that influence meningioma risk (e.g. other 
risk factors such as NF1 status) or early detection (e.g. head MRIs or CTs for other side effects of CNS 
tumors or their treatment) not covered in our study variables. Also, there is a strong correlation 
between CrRT dose and exposed cranial volume (higher doses with partial volumes) as such that no 
meningioma cases were observed among the few patients treated with less than 40 Gy partial CrRT, 
as illustrated in Supplementary Figure 2.   
Owing to clinical reality the radiation exposure metrics we applied tend to overestimate the 
volume of the brain exposed to the summed doses of main field and boost, since the sum of doses is 
assigned to the entire cranium. This is particularly true for medulloblastoma patients. Therefore, the 
true risk may be slightly overestimated in this study. Sensitivity analyses based on the full CrRT dose 
of approximately 30 Gy (i.e. disregarding the additional boost dose of around 24 Gy used in 
medulloblastoma protocols) provide a lower boundary for the estimated dose-related risk.  Of note, 
CCS cohorts include individuals with several characteristics (e.g. radiotherapy, volume, and age, and 
demographic characteristics) that are quite correlated. For example, the proportion of survivors who 
were treated with CrRT declined over time, (from 36% prior to 1985 to 13% during 1995-2001); since 
1985 prophylactic CrRT was eliminated from the DCOG-ALL protocols.16 Moreover, although CrRT 
remained indicated for ALL patients with CNS involvement up to 2004,17 the dose was reduced from 
24 to 18 Gy in 1988.18 
We did not find an effect of sex on meningioma risk, nor was there significant variation in the 
radiation dose-response according to sex, unlike some other studies reporting higher risks among 
women, after adjustment for CrRT dose.2,4,6 
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 Only three previous studies showed some effects of chemotherapy: Two CCSS reports 
indicated increased meningioma risk after treatment with platinum agents without a clear dose-
response.6,7 At face value, these findings seem consistent with our finding of elevated risks 
associated with carboplatin (but not for cisplatin). However, the multivariable models from the cited 
studies6,7 included only a radiotherapy yes/no indicator, which is likely insufficient to fully adjust for 
the radiotherapy dose effects. Importantly, carboplatin can be part of medulloblastoma protocols, a 
patient group considered at highest risk for meningioma because they all received full-CrRT and 
boosts up to total doses exceeding 50 Gy. We question the causality of the carboplatin-meningioma 
association, due to lack of dose-response relation, collinearity with high-risk radiotherapy 
characteristics, no observed meningioma cases among survivors with carboplatin exposure without 
CrRT, no relation of cisplatin with meningioma risk, and no clear evidence on carboplatin 
carcinogenicity from in vitro and in vivo studies. Nonetheless, we cannot entirely discard a true, 
albeit small, effect of carboplatin either.  
In the British Childhood Cancer Survivor Study cohort meningioma risk among individuals 
receiving 1-39, 40-69, and 70 or more mg/m² of intrathecal methotrexate was increased by 15-fold, 
11-fold, and 36-fold, respectively, compared to unexposed survivors.3 The authors added a strong 
cautionary note to their findings: few survivors were treated with intrathecal methotrexate without 
CrRT and no effects were observed for non-intrathecal methotrexate. These findings have not been 
confirmed by other studies, including our results reported here. 
Strengths of our study are the large cohort size with detailed individual treatment 
information and objective and near complete data on histologically confirmed benign meningiomas 
from linkage to the nationwide registry of histo- and cytopathology (PALGA)13 for more than 95% of 
the total cohort. Other studies relied on initial self-report and/or linkage with tumor registries.2,3 In 
addition, a comparison with a sibling group was performed, to obtain more insight into the incidence 
of meningiomas, which enabled us to parallel the meningioma incidence in CCSs to the general 
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population. PALGA is an internationally unique resource to ascertain benign meningiomas, because 
benign CNS tumors are not typically recorded completely in cancer registries, although this is 
changing in more recent years. 
Several weaknesses of our approach deserve attention as well. PALGA has complete national 
coverage from 1990 onwards; tumors occurring during 1968-1989 were not recorded reliably. By 
including only follow-up time since 1990 and the fact that most meningiomas occur >20 years after 
childhood cancer, a follow-up interval which nearly all surviving cohort members completed after 
1990, we are confident that the underestimation of the true cumulative incidence caused by left 
truncation is minimal. Secondly, as in most studies on meningioma, true incidence is likely not 
captured; we report on histologically confirmed benign meningiomas while a certain proportion of 
such tumors can remain asymptomatic/indolent for some time. Other factors may have increased 
the meningioma detection rate: medical care has changed, including access to and indications for 
brain imaging as well as indications for surgery of cranial masses suspect for meningioma. Also, 
between 1996 and 2006, Dutch late effects outpatient clinics were implemented in which CCSs are 
followed-up according to evidence-based Dutch guidelines. These guidelines do not recommend 
active screening for CNS tumors among asymptomatic individuals. Nevertheless, all survivors 
received guideline-based follow-up at fixed intervals, which is more frequent for those with high-
intensity treatment (including those who received radiotherapy). It is quite possible that more 
intensive medical attention in the outpatient clinics slightly increased the detection rates of 
asymptomatic meningioma, for example among patients with a history of seizures, headaches, or 
other neurologic problems owing to a brain tumor or CNS metastases, but also brain surgery, 
hydrocephalus, or high-dose radiotherapy. Longer follow-up of available cohorts with complete 
treatment information and adequate follow-up methods to detect these benign tumors, as well as 
pooled analyses of these studies are needed to shed light on the influence of these issues on 
meningioma incidence rates. 
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 The results of this study can be used to inform surveillance recommendations for long-term 
CCSs who had CrRT, such as those currently being formulated by the International Guideline 
Harmonization Group.19 Although risk estimation in terms of prescribed CrRT dose is necessary in 
light of surveillance guideline development, further studies are forthcoming to express excess risk in 
terms of cranial-volume-based absorbed dose distributions. These will be useful to inform future 
pediatric radiotherapy treatment guidelines. To fully disentangle effects of dose, volume, age, and 
the potential role of chemotherapy agents, an international pooling effort is warranted to achieve 
sufficient statistical power.  
In conclusion, one in eight CCSs exposed to cranial radiotherapy develop a late meningioma 
40 years after childhood cancer diagnosis and this risk is dose- and exposure age-related. We did not 
find significant modifications of the radiation dose-response by age or by exposed cranial volume. 
While the proportion of patients in need of (full) CrRT with curative intent has decreased over time, 
this treatment cannot be abolished without compromising cancer survival for children with 
intracranial tumors or other indications for CrRT. These findings are important to raise awareness 
among survivors, their parents, and care-providers about these long-term sequelae, and to support 
ongoing efforts to reduce the radiation exposure to healthy tissues, where feasible, without 
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Figure 1. Cumulative incidence of meningiomas for survivors with and without cranial radiotherapy 
by time since childhood cancer diagnosis (panel A) and attained age (panel B) and according to 
cranial radiotherapy dose by time since childhood cancer diagnosis (panel C) and attained age (panel 
D), accounting for death as competing risk. 
Figure 2. Cumulative incidence of meningiomas for 5-year survivors according to age at diagnosis 
categories by time since childhood cancer diagnosis (panel A) and attained age (panel B) and 
according to period of childhood cancer diagnosis by time since childhood cancer diagnosis (panel C) 
and attained age (panel D), accounting for death as competing risk. 
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Table 1. Patient characteristics of the DCOG LATER cohort eligible for analyses (N=5,843) for 







  N %   N % 




Leukemia 1,910 33.2 52 53.6 
Non Hodgkin lymphoma 548 9.5 7 7.2 
Hodgkin lymphoma 395 6.9 0 0 
Central nervous system non medulloblastoma 615 10.7 13 13.4 
Medulloblastoma 134 2.3 19 19.6 
Neuroblastoma 313 5.5 0 0 
Retinoblastoma 31 0.5 0 0 
Renal tumors 578 10.1 0 0 
Hepatic tumors 52 0.9 0 0 
Bone tumors 343 6.0 0 0 
Soft tissue tumors 423 7.4 3 3.1 
Germ cell tumors 221 3.9 3 3.1 
Other and unspecified 183 3.2 0 0 
Sex 
    
Male 3,222 56.1 47 48.5 
Female 2,524 43.9 50 51.5 
Age at childhood cancer diagnosis 
    
0-4 y 2,595 45.2 46 47.4 
5-9 y 1,557 27.1 26 26.8 
10-17 y 1,594 27.7 25 25.8 
Calendar year of childhood cancer diagnosis 
    
1963-1984 1,721 30.0 70 72.2 
1985-1994 2,091 36.4 22 22.7 
1995-2001 1,934 33.7 5 5.1 
Attained age at end of follow-up 
    
<20 763 13.3 4 4.1 
20-29 1,975 34.4 36 37.1 
30-39 1,826 31.8 45 46.4 
40+ 1,182 20.6 12 12.4 
Time since childhood cancer diagnosis 
    
<20 2,106 36.7 24 24.7 
20-29 2,062 35.9 47 48.5 
30-39 1,257 21.9 25 25.8 
40+ 321 5.6 1 1.0 
Childhood cancer treatmenta 
    
Surgery only 573 10.0 0 0 
Chemotherapy, no radiotherapy 2,897 50.4 1 1.0 
Radiotherapy, no chemotherapy 428 7.5 17 17.5 
Radiotherapy and chemotherapy 1,775 30.9 79 81.4 
No treatment / treatment unknown 73 1.3 0 0 
CrRT (including TBI)a 
    
Nob 4,522 78.7 3 3.1 
Partial cranial volume 307 5.3 14 14.4 
Full cranial volumec 876 15.3 80 82.5 
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(Continued on the following page) 
Table 1. Patient characteristics of the DCOG LATER cohort eligible for analyses (N=5,843) and 
meningioma patients (N=97) (Cont’d) 
  Total cohort   
Meningioma 
patients 
  N %   N % 




No Head/Cranium or TBI dose 4,522 78.7 3 3.1 
1-19 Gy 314 5.5 10 10.3 
20-39 Gy 397 6.9 48 49.5 
40+ Gy 458 8.0 35 36.1 
Carboplatina 
    
No 5,308 92.4 88 90.1 
Yes 400 7.0 9 9.3 
Hematopoietic cell transplantationa 
    
No 5,314 92.5 90 92.8 
Yes 365 6.4 
 
6 6.2 
WHO grade of first benign meningiomad 
     
1 NA NA 
 
45 80.4 
2 NA NA 
 
11 19.6 




Calender period of first benign meningioma diagnosis 
     
1990-1999 NA NA 
 
12 12.4 
2000-2009 NA NA 
 
47 48.4 
2010-2015e NA NA 
 
38 39.2 
Abbreviations: NA=not applicable; CrRT=cranial radiotherapy; TBI=total body irradiation 
Numbers do not always add up to 100% because of missing values or rounding. 
aTreatment data includes primary treatment and all recurrences; chemotherapy (yes/no), 
radiotherapy (yes/no), and hematopoietic cell transplantation (yes/no) was missing for 32, 32, and 
68 survivors, respectively. 
bIncludes n=163 (2.8%) patients irradiated to facial and other parts of head without cranial 
involvement, no meningioma cases. Of the three patients without a history of CrRT were diagnosed 
with a meningeoma 14,37, and 26 years post-STS (n=2) or post-ALL (n=1), respectively. 
cIncludes n=210 patients treated with TBI, among which 4 developed a meningioma. 
dPercentages were based on cases with a known WHO grade as reported by the pathologist, 
according to the WHO classification in use at the time of diagnosis. 
eIncludes January till April 2015. 
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Table 2. Multivariable Cox regression models for risk of meningioma by demographic and treatment-related risk 
factors (model 1) and additionally by age at diagnosis/cranial radiotherapy dose (model 2), and cranial 
radiotherapy volume/dose (model 3) combinations
a
 
      Model 1   Model 2   Model 3 
  N total N cases HR 95% CI   HR 95% CI   HR 95% CI 
Sex 
 
      
 
    
 
    
Male 3,269 47 REF   
 
REF   
 
REF   





Age at diagnosis 
 
      
 
    
 
    
0-4 y 2,641 46 2.38 1.39-4.07 
 
    
 
2.35 1.40-3.96 
5-9 y 1,583 26 1.09 0.62-1.91 
 
    
 
1.10 0.63-1.94 
10-17 y 1,619 25 REF   
 
    
 
REF   
CrRT exposure 
 
      
 
    
 
    
No CrRT 4,525 3 0.04 0.01-0.15 
 
    
 
    
1-19 Gy 324 10 REF   
 
    
 
    
20-39 Gy 445 48 1.66 0.83-3.33 
 
    
 
    
40+ Gy 493 35 2.81 1.30-6.08 
 
    
 
    
Exposed cranial volume 
 
      
 
    
 
    
Partial CrRT 
 
  REF   
 
    
 
    
Full CrRT 
 




    
Carboplatin 
 
      
 
    
 
    
No 5,396 88 REF   
 
REF   
 
REF   





CrRT exposure (age/dose) 
 
  
   
    
 
    
No CrRT 4,525 3 
   
0.01 0.00-0.05 
 
    
0-4 y / ≤25 Gy 313 31 
   
REF   
 
    
0-4 y / >25 Gy 153 15 
   
1.84 0.95-3.56 
 
    
5+ y  / ≤25 Gy 382 23 
   
0.47 0.27-0.81 
 
    
5+ y / >25 Gy 414 24 
   
0.61 0.33-1.13 
 
    
CrRT exposure (volume/dose) 
 
  
      
    
No CrRT 4,525 3 




 / ≤25 Gy 13 0 





 / >25 Gy 300 14 
      
  
Full CrRT / ≤25 Gy 682 54 
      
1.03 0.56-1.89 
Full CrRT / >25 Gy 267 25 
     
 1.45 0.75-2.83 
Abbreviations: CI=confidence interval; CrRT=cranial radiotherapy; Gy=Gray; HR=Hazard Ratio; N=number; 
REF=reference category 
a
Models include only 96 meningioma cases due to missing values. 
b
Dose groups were collapsed. 
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Table 3. Effect modification of cranial radiotherapy dose-response for risk of meningiomaa 
  N total N cases ERR/Gy 95% CI P interaction 
Model 1: All patients 1,262 93 0.30 0.03-UNKb 
       Model 2: Age at diagnosis 
    
0.86 
0-4 y 2,641 46 0.31 0.10-1.36
 5-9 y 1,583 26 0.31 0.10-1.35 
 10-17 y 1,619 25 0.27 0.08-1.19 
       Model 3: Volume 
    
0.98 
Partial 313 14 0.30 0.09-1.32
 Full 979 79 0.30 0.09-1.29 
       Model 4: Age at diagnosis and volume 
    
0.55 
0-4 y / partial 86 6 0.52 0.13-2.49
 5-17 y / partial 227 8 0.22 0.05-1.06 
 0-4 y / full 380 40 0.29 0.09-1.28 
 5-17 y / full 569 39 0.30 0.09-1.32 
       Model 5: Sex 
    
0.96 
Male 3,269 47 0.30 0.10-1.29
 Female 2,574 50 0.30 0.09-1.28  
Abbreviations: ERR=excess relative risk; Gy=Gray; N=number; UNK=unknown 
aAll models adjusted for sex, age at diagnosis (<5, 5-9, 10+ years), cranial radiotherapy (no, partial, 
full). Coefficients for those variables were fixed at the values estimated in model 1 to improve 
stability of the model fitting. For likelihood ratio tests (P interaction), fixed parameters were 
counted as free, resulting in conservative p-values. 
bDue to a very flat likelihood to the right of the maximum likelihood estimate, even much larger 
values are consistent with the data. 
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   Panel C       Panel D  






No at risk          
Cranial radiotherapy (including TBI) 632 856 998 903 702 542 278 79 
No cranial radiotherapy 3388 3826 3677 2698 1833 1055 557 241 
0 199 583 929 964 816 615 378 146 
9 1746 2813 3256 2903 2142 1347 783 414 
0 1704 2741 3154 2785 2039 1265 721 370 
9 81 182 262 255 200 126 57 15 
0 44 184 367 419 402 350 238 90 
0 113 280 391 396 308 217 144 85 
No at risk          
No cranial radiotherapy 3294 3712 3547 2579 1737 979 510 223 
Cranial radiotherapy dose 1-19 Gy 215 270 275 219 157 110 28 6 
Cranial radiotherapy dose 20-39 Gy 93 239 402 428 395 341 208 54 
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No at risk          
Age at diagnosis <5 years 1787 2114 2113 1651 1188 762 397 178 
Age at diagnosis 5-9 years 1120 1288 1304 996 691 422 214 62 
Age at diagnosis 10-17 years 1145 1309 1285 967 667 420 227 82 
10 1947 2205 1895 1433 987 581 272 98 
0 7 1203 1354 1115 814 539 310 111 
0 0 2 957 1340 1174 852 586 355 
0 199 647 1140 1460 1557 1401 996 550 
6 894 1457 1870 1773 1157 552 172 14 
4 861 1306 1196 655 261 19 0 0 
No at risk         
Period of diagnosis 1963-1984 0 837 1371 1594 1607 1562 838 322 
Period of diagnosis 1985-1994 2113 2020 1976 1924 939 42 0 0 
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